Citations

Showing 10 of 108104 citations.

Significant overall survival improvement in proliferative subtype ovarian cancer patients receiving bevacizumab
Kommoss, Stefan , Winterhoff, Boris , Wang, C, Canzler, Ulrich , Aliferis, Constantin , Belau, Antje , Wang, Junli , Hanker, Lars , Ma, Sisi , Kimmig, Rainer , Tourani, Roshan , Kurzeder, Christian , Mahner, Sven� , Park-Simon, TW, Dowdy, SC, Pfisterer, Jacobus , Heitz, Florian , Kommoss, Felix , Bois, Andreas du , Ma, Sisi , Sehouli, Jalid

Mayo Clinic

Geburtshilfe und Frauenheilkunde | October 29, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1671332 Get It

Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden
Mesa, Ruben A. , Passamonti, Francesco

Mayo Clinic

American Society of Clinical Oncology Educational Book | October 29, 2018 | Volume: No volume available | Issue: 36 | Pages: e324-e335

10.1200/edbk_159322 | PMID 27249739 Get It

Individualized medicine is important for patients with myeloproliferative neoplasms (MPNs), including essential thrombocythemia, polycythemia vera, and myelofibrosis, which are heterogeneous in terms of genetic mutation profile, prognosis, disease burden, and symptoms. Status of MPN driver mutations in JAK2, CALR, and MPL (or lack of one of these mutations) and other myeloid mutations (ASXL1, SRSF2, CBL, and IDH1/2, among others) affects diagnosis and prognosis. Management begins with estimating the prognosis, disease burden including MPN symptoms, and prevention of vascular events. Allogeneic stem cell transplantation is the definitive therapy in a subset of patients with myelofibrosis, the majority of whom receive JAK inhibition with ruxolitinib to relieve splenomegaly and symptoms and to prolong survival. Ruxolitinib is now a second-line therapy in polycythemia vera, with pegylated interferon being evaluated as a potential front-line therapy compared with hydroxyurea. The therapeutic landscape is evolving to include new JAK inhibitors, which may affect cytopenias (pacritinib and momelotinib), combination therapies including ruxolitinib, and novel targets such as pentraxin and telomerase. Assessing the therapeutic efficacy (including symptom impact) and toxicity of these new approaches is necessary to determine longitudinal management of MPNs in clinical practice and is a key component of “individualizing” care for patients with MPNs.
Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer
Azim, Hatem A. , Davidson, Nancy E. , Ruddy, Kathryn J.

Mayo Clinic

American Society of Clinical Oncology Educational Book | October 29, 2018 | Volume: No volume available | Issue: 36 | Pages: 23-32

10.1200/edbk_159069 | PMID 27249683 Get It

For the hundreds of thousands of premenopausal women who are diagnosed annually with endocrine-sensitive breast cancer, treatment strategies are complex. For many, chemotherapy may not be necessary, and endocrine therapy decision making is paramount. Options for adjuvant endocrine regimens include tamoxifen for 5 years, tamoxifen for 10 years, ovarian function suppression (OFS) plus tamoxifen for 5 years, and OFS plus an aromatase inhibitor for 5 years. There are modest differences in efficacy between these regimens, with a benefit from OFS most obvious among patients with higher-risk disease; therefore, choosing which should be used for a given patient requires consideration of expected toxicities and patient preferences. An aromatase inhibitor cannot be safely prescribed without OFS in this setting. Additional research is needed to determine whether genomic tests such as Prosigna and Endopredict can help with decision making about optimal duration of endocrine therapy for premenopausal patients. Endocrine therapy side effects can include hot flashes, sexual dysfunction, osteoporosis, and infertility, all of which may impair quality of life and can encourage nonadherence with treatment. Ovarian function suppression worsens menopausal side effects. Hot flashes tend to be worse with tamoxifen/OFS, whereas sexual dysfunction and osteoporosis tend to be worse with aromatase inhibitors/OFS. Pregnancy is safe after endocrine therapy, and some survivors can conceive naturally. Still, embryo or oocyte cryopreservation should be considered at the time of diagnosis for patients with endocrine-sensitive disease who desire future childbearing, particularly if they will undergo chemotherapy.
Updated Diagnostic Criteria and Staging System for Multiple Myeloma
Rajkumar, S. Vincent

Mayo Clinic

American Society of Clinical Oncology Educational Book | October 29, 2018 | Volume: No volume available | Issue: 36 | Pages: e418-e423

10.1200/edbk_159009 | PMID 27249749 Get It

There has been remarkable progress made in the diagnosis and treatment of multiple myeloma (MM). The median survival of the disease has doubled as a result of several new active drugs. These advances have necessitated a revision of the disease definition and staging of MM. Until recently, MM was defined by the presence of end-organ damage, specifically hypercalcemia, renal failure, anemia, and bone lesions (CRAB features) that can be attributed to the clonal process. In 2014, the International Myeloma Working Group (IMWG) updated the diagnostic criteria for MM to add three specific biomarkers that can be used to diagnose the disease in patients who did not have CRAB features: clonal bone marrow plasma cells greater than or equal to 60%, serum free light chain (FLC) ratio greater than or equal to 100 provided involved FLC level is 100 mg/L or higher, or more than one focal lesion on MRI. In addition, the definition was revised to allow CT and PET-CT to diagnose MM bone disease. These changes enable early diagnosis and allow the initiation of effective therapy to prevent the development of end-organ damage for patients who are at the highest risk. A new staging system has been developed that incorporates high-risk cytogenetic abnormalities in addition to standard laboratory markers of prognosis.
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease
Litzow, Mark R. , Wang, Xin V., Karp, Judith E. , Zhang, Yanming , Luger, Selina M. , Paietta, Elisabeth , Pratz, Keith W. , Altman, Jessica K. , Broun, E. Randolph, Rybka, Witold B. , Rowe, Jacob M. , Tallman, Martin S. , Kaufmann, Scott H. , Pratz, Keith W , Tun, Han Win, Carroll, Martin P , Ketterling, Rhett P. , Lazarus, Hillard M. , Tun, Han W.

Mayo Clinic

American Journal of Hematology | October 29, 2018 | Volume: 94 | Issue: 1 | Pages: 111-117

10.1002/ajh.25333 | PMID 30370956 Get It

To improve the outcome of relapsed/refractory acute myeloid leukemia (AML), a randomized phase II trial of three novel regimens was conducted. Ninety patients were enrolled and were in first relapse or were refractory to induction/re‐induction chemotherapy. They were randomized to the following regimens: carboplatin‐topotecan (CT), each by continuous infusion for 5 days; alvocidib (formerly flavopiridol), cytarabine, and mitoxantrone (FLAM) in a timed sequential regimen; or sirolimus combined with mitoxantrone, etoposide, and cytarabine (S‐MEC). The primary objective was attainment of a complete remission (CR). A Simon two‐stage design was used for each of the three arms. The median age of the patients in the FLAM arm was older at 62 years compared with 55 years for the CT arm and the S‐MEC arm. The overall response was 14% in the CT arm (5/35, 90% CI 7%‐35%), 28% in the FLAM arm (10/36, 90% CI, 16%‐43%), and 16% in the S‐MEC arm (3/19, 90% CI, 4%‐36%). There were nine treatment‐related deaths, seven of which occurred in the FLAM arm with four of these in elderly patients. We conclude that the FLAM regimen had an encouraging response rate and should be considered for further clinical development but should be used with caution in elderly patients.
Microsurgical Anatomy of the Central Core of the Brain
Oliveira, Evandro de, Ribas, Guilherme Carvalhal, Rhoton, Albert L., Ribas, Eduardo Carvalhal , Yağmurlu, Kaan

Mayo Clinic

Arquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery | October 29, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1672356 Get It

The Influence of Depression on Health Care Expenditures Among Adults with Spondylosis, Intervertebral Disc Disorders, and Other Back Problems in the United States
Bilal, Jawad , Berlinberg, Adam , Trost, Jaren R. , Riaz, Irbaz Bin , Bhattacharjee, Sandipan , Riaz, Irbaz B

Mayo Clinic

Pain Medicine | October 29, 2018 | Volume: 21 | Issue: 2 | Pages: e45-e53

10.1093/pm/pny223 | PMID 30445578 Get It

Abstract Background Back pain is a very prevalent complaint, affecting two-thirds of the US population, and it accounts for $100 billion annually in health care expenditures. The occurrence of depression has been reported in existing literature among patients with back pain, but there is limited information regarding health care expenditures among patients with back pain and concurrent depression. Objective To assess excess total and subtypes of health care expenditures among adults with spondylosis, intervertebral disc disorders, and other back problems who reported having depression compared with those without depression in the United States. Methods We utilized a cross-sectional design, pooling Medical Expenditure Panel Survey data from 2010–2012. The eligible study sample included adults (age ≥18 years) who reported positive health care expenditure. Total and subtypes of health care expenditures constituted the dependent variable. Ordinary least squares (OLS) regressions on logged expenditures were performed. Four models were developed to assess influence of demographics, functional ability, and concurrent diagnoses on health care expenditures. Results A total of 6,739 adults with spondylosis, intervertebral disc disorders, and other back problems were assessed, 20.2% (N = 1,316) of whom had concurrent depression. Adults with concurrent depression had significantly higher total health care expenditures ($13,153) compared with the nondepression group ($7,477, P < 0.001). Outpatient and prescription expenditures showed similar findings. After adjusting for demographics, functional disabilities, and comorbidities, excess cost remained higher in the group reporting concurrent depression (46%). Conclusions This study demonstrates that the presence of depression in adults with spondylosis, intervertebral disc disorders, and other back problems is associated with greater economic burden. These findings remained consistent after adjusting for all independent sets of variables. The study’s findings suggest that interventions resulting in better management of depression have the potential to significantly reduce the economic burden in this population.
Idiopathic Cluneal Neuralgia Successfully Treated With Radiofrequency Nerve Ablation: A Case Report
Zheng, Danielle, Lamer, Tim J.

Mayo Clinic

A&A Practice | October 29, 2018 | Volume: 12 | Issue: 10 | Pages: 352-355

10.1213/xaa.0000000000000922 | PMID 30371523 Get It

Middle cluneal nerve entrapment neuropathy/neuralgia (MCN-EN) is a rare and potentially underdiagnosed etiology for chronic low back pain. Symptoms include pain in the buttock and posterior superior iliac spine area that is increased by activity and direct pressure over the area, and is “neuropathic” in nature. Previous case reports describe successful treatment of MCN-EN with nerve block and/or surgical decompression of the MCN. We present a case report detailing the first successful use of radiofrequency nerve ablation in treating MCN-EN.
Pompe Disease Could Mimic Exam Findings of Amyloidosis: Two Rare Diagnoses Bona Fide
Abeykoon, Jithma P. , Duma, Narjust , Tracy, Jennifer A., Milone, Margherita , Go, Ronald S. , Go, Ronald S

Mayo Clinic

Case Reports in Hematology | October 28, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-4

10.1155/2018/9615834 | PMID 30510819 Get It

A 70-year-old female presented with a three-year history of evolving macroglossia causing dysphagia and dysarthria, with proximal muscle weakness. Given the classic physical finding of macroglossia, the patient underwent extensive evaluation for amyloidosis which proved to be negative apart from a bone marrow biopsy which stained positive for transthyretin without amino acid sequence abnormality, thus giving wild-type transthyretin amyloidosis. Since the wild-type transthyretin amyloidosis could not entirely explain her clinical presentation and evaluation, further studies were conducted in a sequential manner, thus leading to a diagnosis of Pompe disease explaining her presenting signs and symptoms including her macroglossia. Through this fascinating case, we attempt to highlight the approach for the diagnoses of two rare diseases in a patient by emphasizing the importance of having a broad differential diagnosis when presented with findings which may have been thought as pathognomonic for certain diseases.